Rs. Walters et al., PHASE-II STUDY OF RECOMBINANT ALPHA-INTERFERON (RIFN-ALPHA) AND CONTINUOUS-INFUSION 5-FLUOROURACIL IN METASTATIC BREAST-CANCER, Journal of immunotherapy with emphasis on tumor immunology, 18(3), 1995, pp. 185-187
Citations number
8
Categorie Soggetti
Immunology,Oncology,"Medicine, Research & Experimental
Twenty-six patients with metastatic breast cancer were offered a phase
IT combination of recombinant a-interferon and continuous-infusion 5-
fluorouracil (5-FU). 5-FU was administered at 750 mg/m(2) daily for 5
days as a continuous infusion acid recombinant interferon at 5 million
U/m(2) subcutaneously days 1, 3, and 5 of each course. The courses we
re repeated every 14 days. Despite moderate nonmyelosuppressive toxici
ty, only two (8%) partial remissions were observed. In this schedule,
the addition of recombinant alpha-interferon to conventional continuou
s-infusion 5-FU resulted in a response rate of 8%.